Ji Chen1, Yan Wang, Xue-Jie Wu, Jun Li, Feng-Qin Hou, Gui-Qiang Wang. 1. Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, No. 8, Xishiku Street, Xicheng District, Beijing 10034, China.
Abstract
AIM: to investigate the effect of pegylated interferon (IFN) α-2b on specific CD8+ T lymphocytes in patients with chronic hepatitis B (CHB). METHODS: twenty-one patients with CHB were treated with pegylated IFN α-2b. Periphery blood mononuclear cells were isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation (density: 1.077 g/L, Pharmingen) at weeks 0, 4, 8, 12, and 24, respectively. Frequency of circulating hepatitis B virus (HBV) epitope-specific CD8 T cells was detected by flow cytometry. Cytokines were detected by cytometric bead assay. RESULTS: the frequency of circulating HBV core or env-specific CD8 T cells was higher (P < 0.05), the number of HBV core specific CD8 T cells was greater at week 24 (P < 0.05), the level of Th1-type cytokines [interleukin (IL)-12, tumor necrosis factor-α, and IFN-γ] was higher, while that of Th2-type cytokines (IL-4, IL-6, and IL-10) was lower in responders than in non-responders (P < 0.05) after pegylated IFN α-2b treatment. The IL-6 level was correlated with HBV DNA (r = 0.597, P = 0.04), while the inducible protein-10 (IP-10) level was correlated with serum alanine aminotransferase (ALT) (r = 0.545, P = 0.005). The IP-10 level at week 8 after pegylated IFN α-2b treatment could predict the normalization of ALT in CHB patients (positive predict value = 56%, negative predict value = 92%). CONCLUSION: pegylated IFN α-2b can enhance the immune response of CHB patients by increasing the frequency of HBV specific CD8+ T cells and regulating the Th1/Th2 cytokines.
AIM: to investigate the effect of pegylated interferon (IFN) α-2b on specific CD8+ T lymphocytes in patients with chronic hepatitis B (CHB). METHODS: twenty-one patients with CHB were treated with pegylated IFN α-2b. Periphery blood mononuclear cells were isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation (density: 1.077 g/L, Pharmingen) at weeks 0, 4, 8, 12, and 24, respectively. Frequency of circulating hepatitis B virus (HBV) epitope-specific CD8 T cells was detected by flow cytometry. Cytokines were detected by cytometric bead assay. RESULTS: the frequency of circulating HBV core or env-specific CD8 T cells was higher (P < 0.05), the number of HBV core specific CD8 T cells was greater at week 24 (P < 0.05), the level of Th1-type cytokines [interleukin (IL)-12, tumor necrosis factor-α, and IFN-γ] was higher, while that of Th2-type cytokines (IL-4, IL-6, and IL-10) was lower in responders than in non-responders (P < 0.05) after pegylated IFN α-2b treatment. The IL-6 level was correlated with HBV DNA (r = 0.597, P = 0.04), while the inducible protein-10 (IP-10) level was correlated with serum alanine aminotransferase (ALT) (r = 0.545, P = 0.005). The IP-10 level at week 8 after pegylated IFN α-2b treatment could predict the normalization of ALT in CHB patients (positive predict value = 56%, negative predict value = 92%). CONCLUSION: pegylated IFN α-2b can enhance the immune response of CHB patients by increasing the frequency of HBV specific CD8+ T cells and regulating the Th1/Th2 cytokines.
Authors: C Ferrari; A Penna; A Bertoletti; A Valli; A D Antoni; T Giuberti; A Cavalli; M A Petit; F Fiaccadori Journal: J Immunol Date: 1990-11-15 Impact factor: 5.422
Authors: Robert Thimme; Stefan Wieland; Carola Steiger; John Ghrayeb; Keith A Reimann; Robert H Purcell; Francis V Chisari Journal: J Virol Date: 2003-01 Impact factor: 5.103
Authors: G F Grady; V A Lee; A M Prince; G L Gitnick; K A Fawaz; G N Vyas; M D Levitt; J R Senior; J T Galambos; T E Bynum; J W Singleton; B F Clowdus; K Akdamar; R D Aach; E I Winkelman; G M Schiff; T Hersh Journal: J Infect Dis Date: 1978-11 Impact factor: 5.226
Authors: Charles E Harvey; Jeffrey J Post; Patricia Palladinetti; Anthony J Freeman; Rosemary A Ffrench; Rakesh K Kumar; George Marinos; Andrew R Lloyd Journal: J Leukoc Biol Date: 2003-09 Impact factor: 4.962
Authors: A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari Journal: J Exp Med Date: 1991-12-01 Impact factor: 14.307